The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer

10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

NCT00885612 ·Status: COMPLETED

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967 ·Status: COMPLETED ·Phase: PHASE3

Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase

NCT03259711 ·Status: COMPLETED

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

NCT00637481 ·Status: COMPLETED ·Phase: PHASE1

Adherence to Aromatase Inhibitors: The Role of Partners

NCT02753985 ·Status: COMPLETED

Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study

NCT00653718 ·Status: COMPLETED

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

NCT00382070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors

NCT01758146 ·Status: UNKNOWN ·Phase: PHASE3

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

NCT00555477 ·Status: TERMINATED ·Phase: PHASE2

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT01124695 ·Status: COMPLETED ·Phase: PHASE2

Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment

NCT01144572 ·Status: COMPLETED

Tamoxifen in Treating Women With Breast Cancer

NCT00003678 ·Status: UNKNOWN ·Phase: PHASE3

Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients"

NCT05103644 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor

NCT01765049 ·Status: ACTIVE_NOT_RECRUITING

Altering Lipids for Tolerance of Aromatase Inhibitor Therapy

NCT04268134 ·Status: COMPLETED ·Phase: PHASE2

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

NCT00516698 ·Status: COMPLETED

Letrozole in Preventing Breast Cancer in Postmenopausal Women

NCT00090857 ·Status: COMPLETED ·Phase: PHASE2

Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients

NCT01954706 ·Status: TERMINATED ·Phase: NA

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

NCT05801705 ·Status: UNKNOWN

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453 ·Status: COMPLETED ·Phase: PHASE1

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

NCT03874325 ·Status: TERMINATED ·Phase: PHASE2

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

NCT00309569 ·Status: COMPLETED ·Phase: PHASE3

Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer

NCT02769104 ·Status: UNKNOWN ·Phase: PHASE3

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

NCT00316836 ·Status: COMPLETED

Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging

NCT05700006 ·Status: COMPLETED